218 reports of this reaction
1.5% of all TERBINAFINE HYDROCHLORIDE reports
#19 most reported adverse reaction
DYSGEUSIA is the #19 most commonly reported adverse reaction for TERBINAFINE HYDROCHLORIDE, manufactured by Aurobindo Pharma Limited. There are 218 FDA adverse event reports linking TERBINAFINE HYDROCHLORIDE to DYSGEUSIA. This represents approximately 1.5% of all 14,851 adverse event reports for this drug.
Patients taking TERBINAFINE HYDROCHLORIDE who experience dysgeusia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSGEUSIA is a less commonly reported adverse event for TERBINAFINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dysgeusia, the following adverse reactions have been reported for TERBINAFINE HYDROCHLORIDE:
The following drugs have also been linked to dysgeusia in FDA adverse event reports:
DYSGEUSIA has been reported as an adverse event in 218 FDA reports for TERBINAFINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSGEUSIA accounts for approximately 1.5% of all adverse event reports for TERBINAFINE HYDROCHLORIDE, making it a notable side effect.
If you experience dysgeusia while taking TERBINAFINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.